Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant (Somavert) effect on insulin resistance in acromegaly
2014-004386-24Phase 3Active
- Sponsor
- University of Naples Federico II
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of pegvisomant in acromegaly, sponsored by University of Naples Federico II. Primary endpoints: Change in fasting plasma glucose with pegvisomant and Change in plasma glucose after oral glucose load with pegvisomant. Started Dec 2020; status: active.
02
Drugs
pegvisomant
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2014-004386-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004386-24.